Member Comments are provided by individuals and reflect their personal opinions only. Under NO circumstances should you act on any advice or opinion posted in this forum. ALWAYS check with your personal physician before taking any action regarding your health! MedHelp International and our partners, sponsors and affiliates have no obligation to monitor any comments posted on this site, or the content and/or accuracy of such exchanges. MedHelp International does not endorse the views of any user.
Mental Health (Expert Forum)
ALZHEIMER'S NEW DRUG - RIVISTIGAMINE
Questions posted in the Mental Health forum are being answered by Dr. Roger L. Gould, author of the Mastering Stress and Depression program and affiliated with the UCLA. Department of Psychiatry. Topics covered include anger, attention deficit disorder (ADD) , bipolar disorder , dementia , electroconvulsive therapy (ECT) , learning disabilities, memory, obsessive compulsive disorder (OCD) , panic , personality disorders, phobias , post-traumatic stress disorder (PTSD) , schizophrenia , stress , transitions, and work problems.
ALZHEIMER'S NEW DRUG - RIVISTIGAMINE
by lola, Feb 24, 2000 12:00AM
MY DOCTOR SAYS THIS NEW DRUG BY NOVARTIS IS BEING HELD UP IN FDA APPROVAL. CAN YOU TELL ME ABOUT IT? ALSO, DO YOU HAVE ANY INFO AS TO WHEN IT MAY BE AVAILABLE? OR, ARE THERE ANY WAYS TO OBTAIN IT ELSEWHERE WHERE IT IS AVAILABLE FOR PUBLIC USE.
THANK YOU
THANK YOU
Doctor's Answer
by HFHS-M.D-HG, Feb 28, 2000 12:00AM
Dear Lola
Rivastigmine (SDZ - ENA 713) is a medication that has been under clinical trials. It is indicated as an oral treatment for patients with mild to severe Alzheimer’s disease. Rivastigmine at a dose of 6 to 12 mg /day was reported to be effective in selected clinical trials. The common adverse effects associated with its use are nausea, vomiting, dizziness, fatigue, urinary incontinence etc. Side effects are reported to be usually mild to moderate, of short duration and respond to lowering the dose. You may try to obtain more information from web site http:///www.alzforum.org. I hope this information is helpful to you.
Sincerely
HFHS-M.D.
Rivastigmine (SDZ - ENA 713) is a medication that has been under clinical trials. It is indicated as an oral treatment for patients with mild to severe Alzheimer’s disease. Rivastigmine at a dose of 6 to 12 mg /day was reported to be effective in selected clinical trials. The common adverse effects associated with its use are nausea, vomiting, dizziness, fatigue, urinary incontinence etc. Side effects are reported to be usually mild to moderate, of short duration and respond to lowering the dose. You may try to obtain more information from web site http:///www.alzforum.org. I hope this information is helpful to you.
Sincerely
HFHS-M.D.
